AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
https://finance.yahoo.com/news/aim-immunotech-reports-additional-patient-120500825.html